gene in individuals relapsing immediately after procedure With all the BCL2 antagonist venetoclax. 66 Resistance to these agents is linked to these mutations in all over 70% of conditions, Whilst they are usually subclonal and their specific function creating resistance must be verified.Not all patients with CLL involve therapy. Inspite of all new